House Rx Secures $55M Series B Funding

Why It Matters

The infusion of capital accelerates House Rx’s rollout of its clinic‑based pharmacy model, positioning it to capture a larger share of the growing specialty drug market and address cost pressures for patients and payers.

Deal Summary

San Francisco‑based health‑tech firm House Rx announced a $55 million Series B round that includes both equity and debt. The round was led by NEA and Town Hall Ventures with participation from LRVHealth, First Round Capital, Bessemer Venture Partners and Silicon Valley Bank, bringing total capital raised to $100 million.